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Genome-wide association studies (GWAS) in schizophrenia have focused on additive allelic effects to identify
disease risk loci. In order to examine potential recessive effects, we applied a novel approach to identify regions
of excess homozygosity in an ethnically homogenous cohort: 904 schizophrenia cases and 1640 controls drawn
from the Ashkenazi Jewish (AJ) population. Genome-wide examination of runs of homozygosity identified an
excess in cases localized to the major histocompatibility complex (MHC). To refine this signal, we used the recently developed GERMLINE algorithm to identify chromosomal segments shared identical-by-descent (IBD)
and compared homozygosity at such segments in cases and controls. We found a significant excess of homozygosity in schizophrenia cases compared with controls in the MHC (P-value 5 0.003). An independent replication cohort of 548 schizophrenia cases from Japan and 542 matched healthy controls demonstrated similar
effects. The strongest case – control recessive effects (P 5 8.81 3 1028) were localized to a 53-kb region near
HLA-A, in a segment encompassing three poorly annotated genes, TRIM10, TRIM15 and TRIM40. At the same
time, an adjacent segment in the Class I MHC demonstrated clear additive effects on schizophrenia risk, demonstrating the complexity of association in the MHC and the ability of our IBD approach to refine localization of
broad signals derived from conventional GWAS. In sum, homozygosity in the classical MHC region appears
to convey significant risk for schizophrenia, consistent with the ecological literature suggesting that homozygosity at the MHC locus may be associated with vulnerability to disease.

INTRODUCTION
Schizophrenia (SCZ) is a severe and chronic psychiatric disorder
that affects 1% of the global population. It is highly heritable
(0.7 – 0.8) (1), but its complex pattern of inheritance has hindered
efforts to identify susceptibility genes. With the advancement of
high-throughput single-nucleotide genotyping technologies,
genome-wide association studies (GWAS) have discovered the
first robust and replicable risk loci for SCZ; however, these
SNPs account for only a tiny proportion of the total genetic
risk (2). Moreover, GWAS generally examine only common
SNPs with additive allelic effects on disease susceptibility, but

such effects contribute only about one-quarter of the variance
in liability to SCZ (3). Therefore, complementary approaches
are required to identify sources of the ‘missing heritability’ of
this phenotype (4,5).
An alternative approach for investigating genetic association
is homozygosity mapping (6). Although homozygosity mapping
was originally developed to identify rare recessive effects in consanguineous families (7), long chromosomal segments of consecutive homozygous alleles can be found throughout the
genome even in outbred individuals (8). These ‘runs of homozygosity’ (ROHs) represent a form of genetic variation that can be
examined for associations with phenotypic variation, which are
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not additive and thus are poorly assessed by standard GWAS
analysis. Such ROHs may harbor rare deleterious variants, and
even in outbred populations, an excess of ROHs may produce
negative phenotypic effects owing to a process similar to inbreeding depression (9,10). Recent evidence has shown that a genomewide excess of ROHs may be associated with increased risk of
SCZ (11,12), as well as Alzheimer’s disease (13). Specific
regions of excess homozygosity have further been implicated in
risk for Alzheimer’s disease (13), rheumatoid arthritis (14) and
autism (15).
Recent studies of ROHs in SCZ and other complex disorders
have been marked by several limitations. First, ROHs are sparsely distributed among individuals from outbred populations,
imposing substantial limitations on power (12). Second, the relative presence of ROHs can be impacted by subtle differences in
ancestry that are difficult to control for in heterogeneous populations, such as European-Americans (16,17). Third, commonly
used methods for the identification of ROHs typically do not distinguish between different alleles that may be homozygous at a
given locus (11). Finally, the presence of ROHs may be a function of common haplotypes and/or lack of recombination at a
given chromosomal locus, rather than having any association
with disease; studies to-date have not directly compared ROH
prevalence against baseline levels of chromosomal sharing.
Recently developed methods utilizing hidden Markov models
to determine identity-by-descent (IBD) of chromosomal segments permit a more precise specification of true autozygosity
(18 –20).
The present study was designed to overcome the aforementioned limitations by examining ROHs in an SCZ case –
control cohort drawn from a homogeneous Ashkenazi Jewish
(AJ) founder population (21). Further, we utilized two complementary methods to examine ROHs, using both segment
length and inferred IBD status to determine ROH thresholds.
In our cohort of 904 AJ SCZ cases and 1640 AJ controls,
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genotyped for 1 million SNPs (Illumina Omni1-Quad platform), we compared the presence of ROHs between cases and
controls using our previously published whole-genome homozygosity association (WGHA) method (11). We then further
refined this signal using an IBD approach: we compared the presence of homozygous or heterozygous tracts of IBD both genomewide as well as on a locus-by-locus basis. Finally, we sought to
replicate our findings in an independent SCZ case – control
cohort from a different ethnically homogeneous (though not
founder) population from Japan.

RESULTS
Principal component analysis (PCA) using ancestry informative
markers (AIMs) that we have previously identified specifically
for the AJ population (21) showed our AJ data set of 904 SCZ
cases and 1640 controls to form a tight cluster (22); similar
results are obtained with standard genome-wide PCA. After
this QC, we performed WGHA in the AJ cohort. Specifically,
we focused on large (.1.5 Mb in length with minimum 300
markers) ROHs for two reasons: (1) It has been shown that
these are more likely to harbor rare, disease-associated variants
(10,12) and (2) a comprehensive examination of ROHs across
multiple worldwide populations has demonstrated that 1.5 Mb
represents a reliable threshold for identifying ROHs that are
due to true autozygosity (homozygosity by descent) (16). Comparing the tally of ROHs in cases versus controls at each locus, a
genome-wide significant signal for excess ROHs within cases
was observed at the MHC locus (P-value ¼ 1.076 × 1025,
FDR ¼ 0.0022) (Fig. 1). However, the observed peak was
quite broad, extending 3 Mb (all P , 0.01 at hg18 coordinates
chr6: 30053249 – 32848389).
We next sought to refine localization of this signal using
the GERMLINE algorithm (18). We also sought to determine
whether these excess ROHs reflected specific haplotypes that

Figure 1. Manhattan plot for ROH analysis. Genome-wide significance threshold was set to P , 2.12 × 1025 owing to non-independence across SNPs (mean 500
SNPs/ROH). The genome-wide significant signal was localized to the chr6 MHC region.
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are shared IBD between significantly larger numbers of case
haplotype carriers compared with control haplotype carriers.
We converted pairwise IBD segments into multi-sample haplotype clusters by using the DASH clustering algorithm (20). In
our AJ data set, DASH analysis identified 1 million haplotype
clusters genome wide. Each subject was then classified as a heterozygous carrier, homozygous carrier or non-carrier of each IBD
segment, and the total number of heterozygous and homozygous
IBD segments detected were counted for each subject.
In order to compare rates of homozygous IBD sharing in cases
and controls, it was first necessary to control for baseline rates of
IBD sharing, which can vary as a function of subtle sampling differences in ancestry (18). Our hypothesis therefore tests the rate of
homozygous IBD sharing, controlling for overall rates of heterozygous IBD sharing using ANCOVA (Tables 1 and 2). Across the
entire genome, we observed that the rate of carriage of homozygous IBD segments (controlling for the rate of heterozygous IBD
sharing) was not significantly increased in SCZ cases compared
with controls (Table 1) For the extended MHC region (Chr6:
25–35 Mb), however, we observed a significantly increased rate
of homozygous IBD segments in cases relative to controls
(P-value ¼ 0.003; Table 1). Both MHC Class I and II regions
show an excess of homozygous IBD segments in SCZ cases

(Table 2), although the latter comparison only trends toward statistical significance owing to the lower overall rate of IBD sharing in
that region. Effect sizes were small, but comparable, across each of
the MHC segments (Cohen’s d ¼ 0.123 for the entire MHC, 0.118
for the Class I MHC and 0.082 for the Class II MHC).
As a replication cohort, we used data from a Japanese GWAS
of 548 patients with SCZ and 542 matched healthy controls with
265,558 markers after QC (23). All subjects were selected from
the Tokai area of the Honshu Island of Japan. Previous studies
have shown that this is an extremely homogeneous population,
with slightly elevated rates of homozygosity compared with
European cohorts (16). As presented in Table 3, we again
observed higher homozygous IBD sharing in cases compared
with controls across the extended MHC region, with comparable
effect sizes as observed in the Ashkenazi cohort. It is important to
note that the overall (genome wide) rate of homozygous IBD
sharing in the outbred (though homogeneous) Japanese cohort
was 30-fold lower than that in the Ashkenazi cohort, greatly
reducing statistical power. However, meta-analysis revealed a
robustly significant effect across the two cohorts (P ¼ 0.0012).
We next focused on individual homozygous IBD segments
within the AJ SCZ cohort to pinpoint the source of the MHC
signal. We performed association tests for IBD segments within

Table 1. Comparison of homozygous and heterozygous IBD segments across the whole genome and extended MHC region (chr6: 25– 35 Mb) in AJ patients and
controls

Homozygous IBD segments
Mean per subject (SD)
Heterozygous IBD segments
Mean per subject (SD)
ANCOVA (Hom controlling Het)

Whole genome
Cases

Controls

MHC locus chr6: 25– 35 MB
Cases

Controls

30.97 (24.19)

29.93 (21.13)

10.23 (17.16)

8.35 (13.08)

7157.9 (913.0)
F1,2541 ¼ 2.56

7,258.6 (715.8)
P ¼ 0.110

123.2 (43.4)
F1,2541 ¼ 8.72

125.14 (42.2)
P ¼ 0.003

Table 2. Comparison of homozygous and heterozygous IBD segments for MHC Class I and II regions in AJ patients and controls

Homozygous IBD segments
Mean per subject (SD)
Heterozygous IBD segments
Mean per subject (SD)
ANCOVA (Hom controlling Het)

MHC Class I region
Cases

Controls

MHC Class II region
Cases

Controls

4.36 (9.59)

3.35 (7.38)

0.60 (2.50)

0.42 (1.86)

57.12 (24.33)
F1,2541 ¼ 8.498

57.67 (23.16)
P ¼ 0.004

17.22 (10.07)
F1,2541 ¼ 3.388

17.73 (9.94)
P ¼ 0.066

Table 3. Comparison of homozygous IBD segments across the extended MHC region (chr6: 25– 35 Mb) in AJ and Japanese cohorts
Homozygous IBD segments at MHC locus chr6: 25–35 Mb
Cases
Ashkenazi Jewish Cohort
Mean per subject (SD)
Japanese Cohort
Mean per subject (SD)

a

Controls

Effect sizea

P-value

10.23 (17.16)

8.35 (13.08)

0.123

0.003b

0.34 (1.66)

0.23 (1.30)

0.074
Meta-analysis

0.196b
0.0012c

Cohen’s d comparison between means of cases and controls.
P-value determined by ANCOVA, controlling for the rate of heterozygous segments.
c
Meta-analytic P-value calculated using Stouffer’s z trend procedure.
b
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Table 4. Association test for IBD region localized to chr6: 30206368–30259349
Model

Allele count cases (carrier/non)

Allele count controls (carrier/non)

Chi-squared statistic

Degrees of freedom

P-value

Additive model
Dominant model
Recessive model

352/1456
306/598
46/858

502/2778
478/1162
24/1616

14.47
6.05
28.62

1
1
1

1.42 × 1024
0.01394
8.81 × 1028

Figure 2. The most significant homozygous IBD segment under the recessive model (shown as red bar) that was associated with SCZ. The top signal was localized to
TRIM10, TRIM15 and TRIM40. The green bar represents the IBD segment with the strongest P-value under the additive model, localized to RNF39 and TRIM31.

the MHC, comparing additive, dominant and recessive models.
Only two segments met the MHC-wide significance threshold
(P , 1.09 × 1024) for any model. As displayed in Table 4, one
segment located at chr6: 30206368–30259349 (hg18) was strongly significant under the recessive model (chi-square ¼ 28.62,
df ¼ 1, P ¼ 8.81 × 1028). Compared with the recessive model,
the chi-square value for this same segment under the additive
model was only half as large with P-value more than 3 orders
of magnitude larger (chi-square ¼ 14.47, df ¼ 1, P ¼ 1.42 ×
1024). This result is especially striking given that the additive
model has enhanced power owing to measuring chromosomes
(2n) rather than individuals (n). As displayed in Figure 2, this
segment localized to the Class I MHC and encompassed three
poorly annotated genes, TRIM10, TRIM15 and TRIM40. In contrast, a neighboring segment (chr6: 30148063–30206302) in the
Class I MHC demonstrated evidence of MHC-wide significant
additive effects (chi-square ¼ 20.19, df ¼ 1, P ¼ 7.03 × 1026),
without evidence of strong recessive effects (Table 5); this
segment contains two genes (RNF39 and TRIM31). No other
IBD segments met the MHC-wide significance threshold under
any model. Supplementary Material, Table S1, displays nine
additional segments that approached significance (nominal
P , 0.001 for any model); of these, seven segments had the
strongest effects under the additive model, whereas two demonstrated strongest effects under the recessive model. These segments spanned both Class I and Class II MHC loci.

DISCUSSION
The major histocompatibility complex (MHC) has emerged as a
region of major interest in SCZ genetics. The first evidence supporting the MHC as a potential SCZ susceptibility locus dates
back to 1974 (24). More recently, large-scale GWAS studies
have converged to demonstrate that the MHC contains the strongest association signal (2,25– 28). Importantly, prior GWAS
studies have been unable to precisely localize the source of
this signal, owing to the extensive long-range linkage disequilibrium throughout the MHC; different studies have identified top
SNPs ranging across a nearly 10-Mb extent (coordinates
ranging from 25 to 35 Mb on Chromosome 6). Additionally,
prior association studies of the MHC have exclusively examined an additive model of risk, in which each additional allele
at a given locus contributes to risk in a linear manner.
The present study has extended prior research on the MHC in
SCZ in two ways. First, we identified a global increase in MHC
homozygosity in SCZ cases compared with controls. Second,
utilizing an IBD approach in our founder population, we were
able to further localize this effect to at least one specific
segment in the Class I MHC; the strongest case – control recessive effects were observed near the HLA-A gene, in a segment
encompassing three poorly annotated genes, TRIM10, TRIM15
and TRIM40. A run of homozygosity in this region, while relatively rare (,2% frequency in AJ controls), conveyed a 3-fold
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Table 5. Association test for IBD region localized to chr6: 30148063– 30206302
Model

Allele count cases (carrier/non)

Allele count controls (carrier/non)

Chi-squared statistic

Degrees of freedom

P-value

Additive model
Dominant model
Recessive model

273/1535
249/655
24/880

355/2925
340/1300
15/1625

19.7
15.2
11.69

1
1
1

9.06 × 1026
9.66 × 1025
6.28 × 1024

increase in the risk for SCZ. At the same time, we observed that
these recessive effects coexist side-by-side with other association signals within the MHC that are more consistent with an
additive effect. In particular, a segment encompassing RNF39
and TRIM31 demonstrated significant additive effects in our
Ashkenazi cohort. While these genes are also poorly annotated,
it is noteworthy that a prior GWAS has detected a strong additive
association with the levels of the MHC component molecule
beta-2 microglobulin to an SNP in TRIM31 (29).
Prior GWAS implicating the MHC in SCZ have been interpreted in the context of growing evidence that immune system
dysfunction might play an important role in the etiology of
SCZ. For example, in epidemiologic studies, several MHClinked autoimmune/inflammatory disorders are found to have
significantly increased prevalence in patients with SCZ (and
their relatives) (30– 32); moreover, exposure to prenatal infections has repeatedly been found to enhance risk of developing
SCZ (33 – 36). Additionally, numerous studies have detected elevated levels of inflammatory markers (e.g. IL-2 and TNF-a)
associated with immune system activation in patients with
SCZ (37– 39). It is important to emphasize that the present
report, as with all genetic association studies, is not able to determine the mechanism by which MHC homozygosity affects risk;
further research is needed in this area.
To the extent that immune mechanisms might be mediating
the observed increase in homozygosity, however, it may be relevant to consider the heterozygote advantage hypothesis of the
MHC. This hypothesis proposes that individuals heterozygous
at MHC loci are able to respond to a greater range of pathogen
peptides than homozygous individuals, and consequently, are
more likely to have higher relative fitness (40– 42). However,
other possible explanations cannot be ruled out: (1) the specific
rare alleles identified in our study may increase susceptibility or
(2) excess homozygosity may mark individuals with increased
risk owing to maternal – fetal HLA matching (43). It should be
noted that a negative result has been reported (44) by a recent
study using a large, well-characterized trio cohort to determine
whether non-random mating, parent-of-origin effects for HLA
alleles and maternal – fetal genotype incompatibility in the
HLA increased risk for SCZ. Because our samples were drawn
from a case– control cohort, further studies would be required
to test this hypothesis more directly.
At the same time, many genes within the MHC are not
primarily related to immune function and point to other possible
neurodevelopmental mechanisms including synaptic plasticity,
neurotransmitter signaling and brain myelination (45). For
example, the class I HLA region includes two non-immunerelated candidate genes for SCZ: MOG, which encodes myelin
oligodendrocyte glycoprotein, a critical constituent of the myelin
sheath which may be aberrant in SCZ (46), and GABBR1, which
encodes a subunit of the metabotropic GABA(B) receptor,

which is also implicated in SCZ pathophysiology (47). Moreover,
HLA molecules themselves have recently been demonstrated to be
directly expressed in the brain at varying levels during early development, even in the absence of infection or insult (48). In a recent
study, the carriers of an SCZ-associated risk allele in the Class I
MHC demonstrated larger ventricular volume (49), consistent
with prior evidence of enlarged ventricles in Class I-deficient
mice (50). It should be noted that the genes identified in our
top recessive segment (TRIM10, TRIM15 and TRIM40) are
only weakly expressed in mouse brain and are variably expressed
in adult human brain according to the Allen Brain Atlas. Therefore, the limited knowledge on the biological function of
TRIM10, TRIM15 and TRIM40 does not allow extensive speculation on the role of these genes in the etiology of the disease.

SUBJECTS AND METHOD
Participants
A total of 1156 SCZ cases from ethnically homogenous population (Ashkenazi Jews) have been collected and ascertained at
the Hebrew University, Israel (Hebrew University Genetic Resource, HUGR, http://hugr.huji.ac.il). Cases were recruited
from hospitalized inpatients at seven medical centers in Israel.
All diagnoses were assigned after direct interview using the
structured clinical interview, a questionnaire with inclusion
and exclusion criteria, and cross-references to medical records.
The inclusion criteria specified that subjects had to be diagnosed
with SCZ or schizoaffective disorder by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), that all four
grandparents of each subject were reported by the subject to be
of AJ ethnic origin, and that each subject or the subject’s legal
representative has signed the informed consent form. The exclusion criteria eliminated subjects diagnosed with at least one of
the following disorders: psychotic disorder owing to a general
medical condition, substance-induced psychotic disorder or
any Cluster A (schizotypal, schizoid or paranoid) personality
disorder. Control samples (n ¼ 2279) from healthy Ashkenazi
individuals were collected from volunteers at the Israeli Blood
Bank; these subjects were not psychiatrically screened but
reported no chronic disease and were taking no medication at
the time of blood draw. Corresponding institutional review
boards and the National Genetic Committee of the Israeli Ministry of Health approved the studies. All samples were fully anonymized immediately after collection.
As a replication cohort, we used data from a Japanese SCZ
GWAS of 575 patients with SCZ and 564 matched healthy controls as previously described (23). All subjects were unrelated,
living in the Tokai area of the mainland of Japan, and selfidentified as Japanese. Patients were included if they (1) met
DSM-IV criteria for SCZ and (2) were physically healthy. Patients
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were excluded if they had a history of substance abuse, neurodevelopmental disorders, epilepsy or known mental retardation.
Consensus diagnoses were made by at least two experienced psychiatrists according to DSM-IV criteria on the basis of unstructured interviews with patients, their families and review of
medical records. Controls were selected from the general population with no history of mental disorders based upon self-report.
After description of the study, written informed consent was
obtained from each subject. This study was approved by the
ethics committees of each participating university.
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identification of ROHs, each subject’s SNP data were then converted to binary calls (0 or 1) at each position indicating whether
that SNP is a member of a ROH for that individual. Next, at each
position, data from all subjects were examined to determine how
many cases and controls share a ROH call at a given position.
There were 708,433 SNP positions, which were part of an ROH
for .1 individual in the cohort; frequency of ROH in cases
versus controls was compared at each such position using chisquare tests. Given that at least 300 consecutive SNPs were to comprise a ROH call, a threshold of P , 0.05/(708433/300) or P ,
2.12 × 1025 was required for genome-wide significance.

Genotyping and quality control
Ashkenazi Jewish samples were genotyped on 1 million
genome-wide SNPs using Illumina HumanOmni1-Quad arrays
according to manufacturers’ specifications. SNP data for the
Japanese SCZ cohort were obtained using the Affymetrix
Human SNP array 5.0. To obtain high-quality data for further
analysis, we performed QC steps for both data sets as follows:
SNPs were filtered on call rate ,98%, minor allele frequency
,0.02 and Hardy–Weinberg exact test P , 0.000001 in controls.
Samples were filtered based on genotype quality control filtration
(sample call rate ,97%, gender mismatch) and examined for
cryptic identity and first- or second-degree relatedness using pairwise IBD estimation (PI_HAT) in PLINK (51) with 128,403 LD
pruned (r 2 . 0.2) genome-wide SNPs. Samples were excluded
based on PI_Hat .0.125; the individual with lower call rate
from each control/control or case/case pair was excluded, and controls were excluded from case–control pairs. After QC, there were
762,372 and 265,558 markers obtained for the AJ data set and
Japan data set, respectively.
Population stratification
To obtain a homogenous population, the AJ samples after QC
were further examined for underlying population stratification
using PCA with AIMs specific for the AJ population (21).
Samples with PCA results suggestive of one or more non-AJ
grandparents were identified as outliers based on first principal
component score of .0.01 and were excluded from further analysis (n ¼ 607). We then compared the remaining AJ samples
with HapMap CEU, JPT and CHB and YRI population. Following sample quality control filters and PCA-based population
homogeneity, a total of 904 AJ SCZ cases and 1640 AJ controls
as well as 548 Japanese SCZ cases and 542 Japanese controls
were included in our IBD analysis. All PCA plots were obtained
using the SVS7 (Golden Helix, Inc.) software package.
Runs of homozygosity
We performed WGHA using the SVS7 software package (GoldenHelix, Inc.) following methods described previously (11). Briefly,
SNP data from each chromosome of each subject were interrogated
for ROHs, which are long series of consecutive SNPs that are
homozygous. Based on prior literature (10,12), we were interested
in long, rare ROHs, so minimum run length was set to 1500 kb
(with minimum 300 SNPs and no gap .100 kb to exclude centromeres and other anomalies). To permit some tolerance for genotyping error, up to one heterozygote call and up to five missing
genotypes were permitted within a called ROH. After the

Identity-by-descent and homozygosity detection
As a complementary approach to identifying homozygosity, we
utilized the GERMLINE algorithm (18), which uses a dynamically adjusted sliding window to detect, across all pairs of
samples, genomic segments shared IBD from a recent ancestor.
Genotype data were first phased using Beagle (version 3.3.2)
(52,53) with default parameters. The phased genotype data
were interrogated for pairwise shared IBD segments using
GERMLINE (18). We ran GERMLINE with parameters tuned
to identify IBD segments of 3 cM or greater, with a window
size of 128 sites and 3 mismatching homozygous sites
allowed. We next executed DASH (20) on the IBD segments
to identify the specific cases and controls sharing each particular
IBD segment. Using in-house perl scripts, we categorized each
segment in each subject as homozygous or heterozygous and
compared rates of homozygous IBD segments in cases versus
controls, controlling for rates of heterozygous sharing, using
ANCOVA (implemented in SPSS 22).
After conducting global tests of homozygous versus heterozygous IBD segments, we sought to localize the source of signal
within the MHC by performing association tests in PLINK.
For each of 457 IBD segments tested in the MHC region, we
compared allelic, dominant and recessive models. We sought to
identify segments that attained significance below a Bonferronicorrected threshold (0.05/457 ¼ 1.09 × 1024) for any of these
models. For each significant segment, we further sought to determine the best fitting model.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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